+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

Novartis AG (NOVN) - Financial and Strategic SWOT Analysis Review

  • PDF Icon

    SWOT Analysis

  • 105 Pages
  • May 2025
  • GlobalData
  • Novartis AG
  • ID: 1314904
Novartis AG (NOVN) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by the analyst to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and the potential opportunities and threats. The profile helps you formulate strategies that augment your business by enabling you to understand your partners, customers and competitors better.

The profile contains critical company information including:

  • Business description - A detailed description of the company’s operations and business divisions.
  • Corporate strategy - Analyst’s summarization of the company’s business strategy.
  • SWOT Analysis - A detailed analysis of the company’s strengths, weakness, opportunities and threats.
  • Company history - Progression of key events associated with the company.
  • Major products and services - A list of major products, services and brands of the company.
  • Key competitors - A list of key competitors to the company.
  • Key employees - A list of the key executives of the company.
  • Executive biographies - A brief summary of the executives’ employment history.
  • Key operational heads - A list of personnel heading key departments/functions.
  • Important locations and subsidiaries - A list and contact details of key locations and subsidiaries of the company.
  • Detailed financial ratios for the past five years - The latest financial ratios derived from the annual financial statements published by the company with 5 years history.
  • Interim ratios for the last five interim periods - The latest financial ratios derived from the quarterly/semi-annual financial statements published by the company for 5 interims history.

Highlights

Novartis AG (Novartis) is a healthcare company that focuses on the discovery, development, manufacture and marketing of prescription and generic pharmaceutical products and eye care products. It provides drugs for the treatment of cancer, cardiovascular diseases, dermatological conditions, neurological disorders, ophthalmic and respiratory diseases, hematologic diseases, solid tumors, immune disorders, and infections, among others. Novartis conducts research in various disease areas through the BioMedical Research division. The company operates through a network of subsidiaries and offices across the Americas, Europe, the Middle East, Africa and Asia-Pacific. Novartis is headquartered in Basel, Switzerland.

Novartis AG Key Recent Developments

  • May 06, 2025: Trinity Life Sciences Reveals Winners of TGaS Advisors Best of Benchmark Awards
  • Apr 29, 2025: Novartis Continues Strong Momentum With Double-Digit Sales Growth, Robust Margin Expansion and Multiple Approvals in Q1
  • Apr 11, 2025: Novartis commits $23bn to US manufacturing amid tariff threats
  • Mar 25, 2025: Novartis to Present New Data at AAN, Including Seven-Year Disability Outcomes and Safety Analysis of Kesimpta in People With Relapsing Multiple Sclerosis

Key benefits of buying this profile include:

You get detailed information about the company and its operations to identify potential customers and suppliers.
  • The profile analyzes the company’s business structure, operations, major products and services, prospects, locations and subsidiaries, key executives and their biographies and key competitors.
Understand and respond to your competitors’ business structure and strategies, and capitalize on their weaknesses. Stay up to date on the major developments affecting the company.
  • The company’s core strengths and weaknesses and areas of development or decline are analyzed and presented in the profile objectively. Recent developments in the company covered in the profile help you track important events.
Equip yourself with information that enables you to sharpen your strategies and transform your operations profitably.
  • Opportunities that the company can explore and exploit are sized up and its growth potential assessed in the profile. Competitive and/or technological threats are highlighted.
Scout for potential investments and acquisition targets, with detailed insight into the companies’ strategic, financial and operational performance.
  • Financial ratio presented for major public companies in the profile include the revenue trends, profitability, growth, margins and returns, liquidity and leverage, financial position and efficiency ratios.
Gain key insights into the company for academic or business research.
  • Key elements such as SWOT analysis, corporate strategy and financial ratios and charts are incorporated in the profile to assist your academic or business research needs.
Note: Some sections may be missing if data is unavailable for the company

Table of Contents

Section 1 - About the Company
  • Novartis AG - Key Facts
  • Novartis AG - Key Employees
  • Novartis AG - Key Employee Biographies
  • Novartis AG - Major Products and Services
  • Novartis AG - History
  • Novartis AG - Company Statement
  • Novartis AG - Locations And Subsidiaries
  • Head Office
  • Other Locations & Subsidiaries
  • Joint Venture
Section 2 - Company Analysis
  • Company Overview
  • Novartis AG - Business Description
  • Geographical Segment: Asia/Africa/Australasia
  • Performance
  • Geographical Segment: Canada and Latin America
  • Performance
  • Geographical Segment: Europe
  • Performance
  • Geographical Segment: US
  • Performance
  • R&D Overview
  • Novartis AG - Corporate Strategy
  • Novartis AG - SWOT Analysis
  • SWOT Analysis - Overview
  • Novartis AG - Strengths
  • Novartis AG - Weaknesses
  • Novartis AG - Opportunities
  • Novartis AG - Threats
  • Novartis AG - Key Competitors
Section 3 - Company Financial Ratios
  • Financial Ratios - Capital Market Ratios
  • Financial Ratios - Annual Ratios
  • Performance Chart
  • Financial Performance
  • Financial Ratios - Interim Ratios
  • Financial Ratios - Ratio Charts
Section 4 - Company’s Lifesciences Financial Deals and Alliances
  • Novartis AG, Pharmaceuticals & Healthcare, Deals By Year, 2019 to YTD 2025
  • Novartis AG, Pharmaceuticals & Healthcare, Deals By Type, 2019 to YTD 2025
  • Novartis AG, Recent Deals Summary
Section 5 - Company’s Recent Developments
  • May 06, 2025: Trinity Life Sciences Reveals Winners of TGaS Advisors Best of Benchmark Awards
  • Apr 29, 2025: Novartis Continues Strong Momentum With Double-Digit Sales Growth, Robust Margin Expansion and Multiple Approvals in Q1
  • Apr 11, 2025: Novartis commits $23bn to US manufacturing amid tariff threats
  • Mar 25, 2025: Novartis to Present New Data at AAN, Including Seven-Year Disability Outcomes and Safety Analysis of Kesimpta in People With Relapsing Multiple Sclerosis
  • Jan 31, 2025: Novartis Continues Strong Momentum of Sales Growth With Margin Expansion, Reaches Key Innovation Milestones in 2024
  • Jan 31, 2025: Novartis continues strong momentum of sales growth with margin expansion, reaches key innovation milestones in 2024
  • Jan 13, 2025: Illumina Launches Pilot Proteomics Program With UK Biobank and Biopharma Collaborators to Analyze 50,000 Samples
  • Dec 19, 2024: ACCIONA Energia installs a battery storage system at the Extremadura I-II-III photovoltaic plant
  • Dec 04, 2024: Novartis Canada Awards More Than $680,000 to Community-Based Programs Aimed At Advancing Health Equity
  • Nov 25, 2024: Novartis highlights new 96-week results from Phase III Scemblix ASC4FIRST trial at ASH and late-breaking analysis from Phase III Kisqali NATALEE trial at SABCS
Section 6 - Appendix
  • Methodology
  • Ratio Definitions
  • About the Analyst
  • Contact the Publisher
  • Disclaimer
List of Tables
  • Novartis AG, Key Facts
  • Novartis AG, Key Employees
  • Novartis AG, Key Employee Biographies
  • Novartis AG, Major Products and Services
  • Novartis AG, History
  • Novartis AG, Subsidiaries
  • Novartis AG, Joint Venture
  • Novartis AG, Key Competitors
  • Novartis AG, Ratios based on current share price
  • Novartis AG, Annual Ratios
  • Novartis AG, Interim Ratios
  • Novartis AG, Pharmaceuticals & Healthcare, Deals By Year, 2019 to YTD 2025
  • Novartis AG, Pharmaceuticals & Healthcare, Deals By Type, 2019 to YTD 2025
  • Novartis AG, Recent Deals Summary
  • Currency Codes
  • Capital Market Ratios
  • Equity Ratios
  • Profitability Ratios
  • Cost Ratios
  • Liquidity Ratios
  • Leverage Ratios
  • Efficiency Ratios
List of Figures
  • Novartis AG, Performance Chart (2020 - 2024)
  • Novartis AG, Ratio Charts
  • Novartis AG, Pharmaceuticals & Healthcare, Deals By Year, 2019 to YTD 2025
  • Novartis AG, Pharmaceuticals & Healthcare, Deals by Type, 2019 to YTD 2025

Companies Mentioned (Partial List)

A selection of companies mentioned in this report includes, but is not limited to:

  • Verona Pharma Plc
  • Takeda Pharmaceutical Co Ltd
  • Sanofi
  • Pfizer Inc
  • Novo Nordisk AS
  • Merck & Co Inc
  • Johnson & Johnson
  • GSK plc
  • Gilead Sciences Inc
  • F. Hoffmann-La Roche Ltd
  • Eli Lilly and Co
  • Bristol-Myers Squibb Co
  • Biogen Inc
  • AstraZeneca Plc
  • Amgen Inc
  • AbbVie Inc